Amedisys Inc (NASDAQ:AMED) Director Linda J. Hall sold 5,256 shares of Amedisys stock in a transaction that occurred on Saturday, November 9th. The shares were sold at an average price of $120.00, for a total transaction of $630,720.00. Following the completion of the sale, the director now owns 17,169 shares of the company’s stock, valued at $2,060,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Amedisys stock opened at $118.20 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. Amedisys Inc has a 1-year low of $49.98 and a 1-year high of $140.91. The firm has a market capitalization of $3.64 billion, a PE ratio of 53.48, a PEG ratio of 1.51 and a beta of 1.43.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.18. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The business had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. During the same period in the previous year, the company earned $0.56 earnings per share. Amedisys’s revenue for the quarter was up 11.7% on a year-over-year basis. As a group, analysts anticipate that Amedisys Inc will post 3.58 EPS for the current year.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Amedisys by 14.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares during the last quarter. Vanguard Group Inc raised its stake in Amedisys by 14.3% during the 3rd quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Amedisys by 14.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after purchasing an additional 118,936 shares during the last quarter. Acadian Asset Management LLC raised its stake in Amedisys by 218.9% during the 3rd quarter. Acadian Asset Management LLC now owns 609,586 shares of the health services provider’s stock valued at $76,177,000 after purchasing an additional 418,424 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in Amedisys by 141.4% during the 3rd quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock valued at $49,551,000 after purchasing an additional 232,255 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.wkrb13.com/2019/01/11/linda-j-hall-sells-5256-shares-of-amedisys-inc-amed-stock.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.